


CLAIMS

1. A compound of Formula (I):



or a pharmaceutically acceptable salt thereof, wherein:

X is -NH- , and R^1 is -CH(OH)-Y ;

or

X is $\text{-CH}_2\text{-}$, and R^1 is -CH(OH)-Y or $\text{-SO}_2\text{R}^2$ where R^2 is $\text{C}_1\text{-C}_3$ alkyl;

R^3 is H or halo;

Y is selected from a 5-membered heteroaryl ring containing 1-3 heteroatoms selected from N, O and S as ring members, phenyl, and C_{1-3} alkyl, and each Y is optionally substituted with one to three R^4 ;

each R^4 is independently selected from halo, C_{1-3} alkyl, and C_{3-6} cycloalkyl, wherein the C_{1-3} alkyl and C_{3-6} cycloalkyl are each optionally substituted with up to three groups selected from halo, CN and -OH ;

L is $\text{-C}\equiv\text{C-}$ or $\text{-CR}^5\text{=CR}^5\text{-}$;

R^5 is independently selected at each occurrence from H, halo and methyl;

and


Z is selected from C_{1-6} alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, pyridinyl, and phenyl, each of which is optionally substituted with up to three groups selected from halogen, hydroxy, C_{1-4} alkoxy, C_{1-4} haloalkoxy, CN, and C_{1-4} alkyl that is optionally substituted with one to three groups selected from halogen, hydroxy, amino, CN, and C_{1-3} alkoxy;

or, when L is $\text{-CR}^5\text{=CR}^5\text{-}$, Z taken together with one of the R^5 groups and any atoms connecting Z with the R^5 group can form a 3-7 membered cycloalkyl or cycloalkenyl group that is optionally substituted with up to three groups selected from halogen, hydroxy, C_{1-4} alkoxy, C_{1-4} haloalkoxy, CN, and C_{1-4} alkyl that is optionally substituted with one to three groups selected from halogen, hydroxy, amino, CN, and C_{1-3} alkoxy.

2. The compound of claim 1, wherein R^1 is $\text{-SO}_2\text{R}^2$.

3. The compound of claim 1 or 2, wherein X is $\text{-CH}_2\text{-}$.

4. The compound of any of claims 1-3, wherein Z is C₁-C₄ alkyl or C₃-C₆ cycloalkyl, and Z is optionally substituted with up to three groups selected from halogen, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, CN, and C₁₋₄ alkyl optionally substituted with one to three groups selected from halogen, hydroxy, amino, CN, and C₁₋₃ alkoxy.
5. The compound of any of the preceding claims, wherein L is $\text{--C}\equiv\text{C--}$.
6. The compound of claim 1, wherein the compound is of Formula (II):



7. A compound of claim 1, wherein the compound is selected from the group consisting of
 - (R)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,
 - (R)-4-(5-(cyclobutylethynyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,
 - (R)-4-(5-(3,3-dimethylbut-1-yn-1-yl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,
 - (R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(5-(prop-1-yn-1-yl)isoxazol-3-yl)butanamide,
 - (R)-4-(5-(but-1-yn-1-yl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,
 - (R)-N-hydroxy-2-methyl-4-(5-(3-methylbut-1-yn-1-yl)isoxazol-3-yl)-2-(methylsulfonyl)butanamide,
 - (R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(5-(pent-1-yn-1-yl)isoxazol-3-yl)butanamide,
 - (R)-N-hydroxy-2-methyl-4-(5-((1-methylcyclopropyl)ethynyl)isoxazol-3-yl)-2-(methylsulfonyl)butanamide,
 - (R)-4-(5-(5-fluorobut-1-yn-1-yl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(5-(5-fluoropent-1-yn-1-yl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(5-(5,5-difluoropent-1-yn-1-yl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(5-((3,3-difluorocyclobutyl)ethynyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(5-((3-fluorocyclobutyl)ethynyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(5-(5-hydroxy-5-methylhex-1-yn-1-yl)isoxazol-3-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(5-((3-(methoxymethyl)cyclobutyl)ethynyl)isoxazol-3-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(5-((3-(2-hydroxypropan-2-yl)cyclobutyl)ethynyl)isoxazol-3-yl)-2-methyl-2-(methylsulfonyl)butanamide,

N-hydroxy-4-(5-((4-(hydroxymethyl)phenyl)ethynyl)isoxazol-3-yl)-2-methyl-2-(methylsulfonyl)butanamide,

N-hydroxy-4-(5-((4-(2-hydroxyethyl)phenyl)ethynyl)isoxazol-3-yl)-2-methyl-2-(methylsulfonyl)butanamide,

N-hydroxy-4-(5-((4-(2-hydroxy-1-methoxyethyl)phenyl)ethynyl)isoxazol-3-yl)-2-methyl-2-(methylsulfonyl)butanamide,

N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(5-(phenylethynyl)isoxazol-3-yl)butanamide,

N-hydroxy-4-(5-((4-((R)-2-hydroxypropyl)phenyl)ethynyl)isoxazol-3-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-N-hydroxy-4-(5-((4-((S)-2-hydroxy-1-methoxyethyl)phenyl)ethynyl)-isoxazol-3-yl)-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(5-((4-((S)-1,2-dihydroxyethyl)phenyl)ethynyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R)-4-(5-((4-((R)-1,2-dihydroxyethyl)phenyl)ethynyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(2S,3R)-2-(((5-(cyclopropylethynyl)isoxazol-3-yl)methyl)amino)-N,3-dihydroxy-2-methyl-3-(5-methylisoxazol-3-yl)propanamide,

(2S,3R)-2-(((5-(cyclobutylethynyl)isoxazol-3-yl)methyl)amino)-N,3-dihydroxy-2-methyl-3-(5-methylisoxazol-3-yl)propanamide,

(2S,3R)-N,3-dihydroxy-2-methyl-3-(5-methylisoxazol-3-yl)-2-(((5-(phenylethynyl)isoxazol-3-yl)methyl)amino)propanamide,

N,3-dihydroxy-3-(5-(hydroxymethyl)isoxazol-3-yl)-2-methyl-2-(((5-(phenylethynyl)isoxazol-3-yl)methyl)amino)propanamide,

(2S,3R)-N,3-dihydroxy-2-(((5-(6-methoxyhex-1-yn-1-yl)isoxazol-3-yl)methyl)amino)-2-methyl-3-(5-methylisoxazol-3-yl)propanamide,

2-(((5-(cyclopropylethynyl) isoxazol-3-yl) methyl) amino)-3-(5-cyclopropylisoxazol-3-yl)-N, 3-dihydroxy-2-methylpropanamide,

(R,E)-4-(5-(but-1-en-1-yl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R,E)-4-(5-(2-cyclopropylvinyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R,E)-4-(5-(but-2-en-2-yl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R,Z)-4-(5-(but-2-en-2-yl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R,Z)-4-(5-(2-cyclopropyl-1-fluorovinyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R,E)-4-(5-(2-cyclopropyl-1-fluorovinyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

(R,Z)-4-(5-(2-cyclopropyl-2-fluorovinyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide, and

(R)-4-(5-(cyclohex-1-en-1-yl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

or a pharmaceutically acceptable salt thereof.

8. A compound of claim 1, which is

(R)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide,

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition, comprising:

a compound according to any of claims 1 to 8 and
a pharmaceutically acceptable carrier.

10. A pharmaceutical combination, comprising:

a compound according to any of claims 1 to 8,
an antibacterially effective amount of a second therapeutic agent, and
a pharmaceutically acceptable carrier.

11. The pharmaceutical combination according to claim 10, wherein the second

therapeutic agent is selected from the group consisting of Ampicillin, Piperacillin, Penicillin G, Ticarcillin, Imipenem, Meropenem, Azithromycin, Erythromycin, Aztreonam, Cefepime, Cefotaxime, Ceftriaxone, Ceftazidime, Ciprofloxacin, Levofloxacin, Clindamycin, Doxycycline, Gentamycin, Amikacin, Tobramycin, Tetracycline, Tigecycline, Rifampicin, Vancomycin and Polymyxin.

12. A compound according to claims 1 to 8 or a pharmaceutically acceptable salt thereof, for use as a medicament.

13. A compound according to claims 1 to 8 or a pharmaceutically acceptable salt thereof, for use in treatment of a Gram-negative bacterial infection.

14. A compound according to claims 1 to 8 or a pharmaceutically acceptable salt thereof, for use in treatment of a Gram-negative bacterial infection, wherein the bacterial infection is selected from the Pseudomonadales and Enterobacteriaceae species which is selected from the group consisting of *Pseudomonas*, *Acinetobacter*, *Stenotrophomonas*, *Burkholderia*, *Serratia*, *Proteus*, *Klebsiella*, *Enterobacter*, *Citrobacter*, *Salmonella*, *Shigella*, *Providencia*, *Morganella*, *Cedecea*, *Yersina* and *Edwardsiella* species and *Escherichia coli*.

15. The compound for use according to claim 13, wherein the compound of Formula (I) is used in combination with an immunomodulator.